NewEdge Advisors LLC lessened its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 29.4% in the first quarter, according to its most recent filing with the SEC. The firm owned 14,764 shares of the exchange traded fund’s stock after selling 6,155 shares during the quarter. NewEdge Advisors LLC’s holdings in SPDR S&P Biotech ETF were worth $1,886,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of XBI. Bank of America Corp DE increased its holdings in shares of SPDR S&P Biotech ETF by 13.3% during the first quarter. Bank of America Corp DE now owns 14,518,027 shares of the exchange traded fund’s stock valued at $1,854,388,000 after purchasing an additional 1,700,851 shares during the period. Morgan Stanley raised its stake in shares of SPDR S&P Biotech ETF by 8.3% during the fourth quarter. Morgan Stanley now owns 11,491,683 shares of the exchange traded fund’s stock valued at $1,401,181,000 after purchasing an additional 882,718 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in SPDR S&P Biotech ETF by 75.7% in the fourth quarter. Wells Fargo & Company MN now owns 3,566,265 shares of the exchange traded fund’s stock worth $434,835,000 after purchasing an additional 1,536,122 shares during the period. Avoro Capital Advisors LLC acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter worth about $256,053,000. Finally, Bessemer Group Inc. grew its position in SPDR S&P Biotech ETF by 13.5% in the 4th quarter. Bessemer Group Inc. now owns 1,853,232 shares of the exchange traded fund’s stock valued at $225,965,000 after buying an additional 220,244 shares in the last quarter.
SPDR S&P Biotech ETF Stock Down 2.9%
Shares of XBI opened at $147.01 on Friday. The firm has a market capitalization of $9.70 billion, a PE ratio of 11.47 and a beta of 0.82. The firm has a 50-day moving average price of $146.16 and a 200 day moving average price of $134.34. SPDR S&P Biotech ETF has a 52-week low of $84.39 and a 52-week high of $165.71.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Read More
- Five stocks we like better than SPDR S&P Biotech ETF
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
